Panobinostat

Search with Google Search with Bing

Information
Drug Name
Panobinostat
Description
Entry(CIViC)
1
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
uveal melanoma BAP1 MUTATION BAP1 MUTATION D Predictive Supports Sensitivity/Response Somatic 3 22038994 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Somatic and germline BAP1 mutations are associated... BAP1 BAP1 MUTATION BAP1 MUTATION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT01658241 Completed Phase 2 Panobinostat Biological Correlates Study July 16, 2012 March 18, 2015
NCT01651039 Completed Phase 2 Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) July 2012 December 21, 2016
NCT02890069 Completed Phase 1 A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat October 14, 2016 February 22, 2022
NCT02722941 Completed Phase 2 Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) June 10, 2016 January 18, 2021
NCT00667862 Completed Phase 2 Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer March 18, 2008 November 5, 2010
NCT00670553 Completed Phase 1 A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer September 2008 January 2010
NCT00686218 Completed Phase 1 Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia May 2008 August 2014
NCT02588339 Completed Phase 2 Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention March 4, 2016 July 13, 2021
NCT00742027 Completed Phase 2 Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma September 16, 2008 August 12, 2013
NCT00743288 Completed Phase 1/Phase 2 Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma July 2008 December 2012
NCT00777049 Completed Phase 2 Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer February 2009 April 2015
NCT00840346 Completed Phase 1/Phase 2 Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) September 2009 December 2018
NCT01549431 Completed Phase 1 Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma January 2012 April 2017
NCT01613976 Completed Phase 1 A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients August 2012 May 2014
NCT02506959 Completed Phase 2 Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma September 14, 2015 June 3, 2024
NCT00878436 Completed Phase 1/Phase 2 Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration June 2009 July 2015
NCT00878904 Completed Phase 1 Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors September 13, 2009 October 10, 2016
NCT02471430 Completed Phase 1/Phase 2 Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy May 2016 December 2023
NCT00918333 Completed Phase 1/Phase 2 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma June 2009 July 16, 2019
NCT00962507 Completed Phase 1 Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma July 2009 January 2013
NCT00967044 Completed Phase 1/Phase 2 Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma November 2009 March 2014
NCT01023308 Completed Phase 3 Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma December 21, 2009 July 30, 2015
NCT01034163 Completed Phase 3 A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) June 2010 May 2012
NCT02057640 Completed Phase 1/Phase 2 MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma May 22, 2014 May 15, 2018
NCT01083602 Completed Phase 2 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma June 2010 February 2014
NCT01105312 Completed Phase 1/Phase 2 Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer September 2010 September 3, 2013
NCT02032810 Completed Phase 1 Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma January 7, 2014 September 25, 2019
NCT01965353 Completed Phase 1 A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma October 2013 September 2021
NCT01169636 Completed Phase 1/Phase 2 Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma January 31, 2011 May 17, 2017
NCT01802879 Completed Phase 2 Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator June 24, 2013 November 19, 2018
NCT01242774 Completed Phase 1 Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) October 2010 May 2014
NCT00425555 Completed Phase 2 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma January 2007 June 2013
NCT01261247 Completed Phase 2 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma January 17, 2011 December 2, 2019
NCT01301807 Completed Phase 1 Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma July 28, 2011 November 7, 2019
NCT01321346 Completed Phase 1 A Study Of Panobinostat In Children With Refractory Hematologic Malignancies March 2011
NCT01693601 Completed Phase 1/Phase 2 Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) January 2013 May 18, 2018
NCT01433445 Completed Phase 1 Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis November 1, 2011 June 22, 2020
NCT01440582 Completed Phase 1 Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients February 18, 2013 February 28, 2019
NCT01680094 Completed Phase 1/Phase 2 Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART September 2012 January 2014
NCT01460940 Completed Phase 2 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma October 13, 2011 November 16, 2016
NCT01463046 Completed Phase 1 Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome January 2012 December 2018
NCT01496118 Completed Phase 1/Phase 2 Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma December 2011 December 2020
NCT01504776 Completed Phase 1 Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) April 2011 September 2014
NCT01523834 Completed Phase 2 Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT February 2011 April 2017
NCT02568943 No longer available An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
NCT02204553 No longer available Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
NCT05725200 Recruiting Phase 2 Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer September 27, 2022 December 31, 2040
NCT01245179 Recruiting Phase 1 Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease November 2010 March 2026
NCT02386800 Recruiting Phase 4 CINC424A2X01B Rollover Protocol March 5, 2015 September 16, 2027
NCT01582009 Terminated Phase 1/Phase 2 Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate March 2010 December 2015
NCT01324635 Terminated Phase 1 Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors May 2012 October 2016
NCT01238965 Terminated Phase 1 Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy October 2010 April 2015
NCT00723203 Terminated Phase 2 Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia April 2008 September 2010
NCT02676323 Terminated Phase 1 Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome May 3, 2016 April 9, 2018
NCT00594230 Terminated Phase 2 LBH589 in Refractory Myelodysplastic Syndromes (MDS) January 2008 March 2011
NCT00567879 Terminated Phase 1/Phase 2 A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab April 2008 May 2011
NCT03256045 Terminated Phase 2 Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma February 8, 2018 February 5, 2021
NCT03878524 Terminated Phase 1 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial April 1, 2020 December 10, 2020
NCT04326764 Terminated Phase 3 Panobinostat Maintenance After HSCT fo High-risk AML and MDS July 24, 2018 February 13, 2023
NCT04341311 Terminated Phase 1 Phase I Study of Marizomib + Panobinostat for Children With DIPG August 10, 2020 February 14, 2024
NCT04897880 Terminated Phase 2 A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT January 9, 2019 December 24, 2021
NCT01056601 Terminated Phase 2 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy September 2010 February 2011
NCT00931762 Terminated Phase 2 A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis August 31, 2009 August 29, 2011
NCT00490776 Terminated Phase 2 Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) July 5, 2007 September 22, 2009
NCT00891033 Terminated Phase 1 Panobinostat/Velcade in Multiple Myeloma April 2009 August 2013
NCT00873002 Terminated Phase 1 Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery March 2009 June 2010
NCT02518750 Terminated Phase 2 Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma November 23, 2016 March 11, 2018
NCT00848523 Terminated Phase 2 Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors November 2008 April 2009
NCT01884428 Unknown status Phase 1 Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma July 2011 December 2015
NCT02145715 Unknown status Phase 1/Phase 2 Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma January 2013 January 2016
NCT01451268 Unknown status Phase 1/Phase 2 Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) January 2011 April 2018
NCT02802163 Withdrawn Phase 1/Phase 2 Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat June 2017 December 2020
NCT03982134 Withdrawn Phase 1 PDR001 + Panobinostat for Melanoma and NSCLC September 2019 May 1, 2022
NCT03632317 Withdrawn Phase 2 A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas October 2019 October 2025
NCT02961816 Withdrawn Phase 2 Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma June 2017 June 2021
NCT01160731 Withdrawn Phase 1 Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer November 2009
NCT01115036 Withdrawn Phase 2 A Panobinostat Presurgery April 2010 April 2012